A61K 47/6821
Plant heterodimeric toxins
Official title: {Plant heterodimeric toxins, e.g. abrin or modeccin}
A61K47/6821 (Plant heterodimeric toxins) appears on 34 US grants and 47 published applications in this corpus.
Search patents in A61K- Granted patents
- 34
- Published applications
- 47
- Assignees
- 36
- Inventors
- 89
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 2 |
| 2004 | 1 | 1 |
| 2005 | 0 | 2 |
| 2006 | 2 | 3 |
| 2007 | 1 | 0 |
| 2008 | 1 | 2 |
| 2009 | 1 | 3 |
| 2010 | 3 | 3 |
| 2011 | 1 | 2 |
| 2012 | 2 | 2 |
| 2013 | 1 | 1 |
| 2014 | 1 | 0 |
| 2015 | 1 | 4 |
| 2016 | 1 | 1 |
| 2017 | 3 | 2 |
| 2018 | 1 | 2 |
| 2019 | 1 | 2 |
| 2020 | 1 | 1 |
| 2021 | 0 | 2 |
| 2022 | 1 | 3 |
| 2023 | 2 | 2 |
| 2024 | 1 | 2 |
| 2025 | 0 | 2 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s)24 Mar 2026US 12,582,658 B2Oregon Health & Science University
- Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor13 Aug 2024US 12,059,500 B2Oregon Health & Science University
- Monoclonal antibodies against Claudin-18 for treatment of cancer29 Aug 2023US 11,739,139 B2Astellas Pharma Inc.
- Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor20 Jun 2023US 11,679,082 B2Oregon Health & Science University
- Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor18 Jan 2022US 11,224,573 B2Oregon Health & Science University
- Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s)7 May 2026US 2026/0124210 A1Oregon Health & Science University
- Antibodies and variants thereof against human b7-h312 Jun 2025US 2025/0188167 A1Nanjing Probio Biotech Co., Ltd.
- Integrin Alpha10 Antibody5 Jun 2025US 2025/0179190 A1Targinta AB
- Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s)21 Nov 2024US 2024/0382492 A1Oregon Health & Science University
- Monoclonal antibodies against claudin-18 for treatment of cancer11 Apr 2024US 2024/0117022 A1Astellas Pharma Inc.
Most cited
By later US patents
- 27411, a novel human PGP synthase93US 7,029,895 B2Millennium Pharmaceuticals, Inc. · 2006
- Ubiquitin protease87US 7,482,147 B2Millennium Pharmaceuticals, Inc. · 2009
- Ubiquitin protease57US 7,776,577 B2Millennium Pharmaceuticals, Inc. · 2010
- Monoclonal antibodies against claudin-18 for treatment of cancer39US 8,168,427 B2Ganymed Pharmaceuticals AG · 2012
- Gelonin immunotoxin31US 4,888,415 ADana-Farber Cancer Institute, Inc. · 1989